Gemcitabine Hydrochloride Global Market Report 2025

The gemcitabine hydrochloride market size is expected to see strong growth in the next few years. It will grow to $1.1 billion in 2029 at a compound annual growth rate (CAGR) of 7%. The projected growth in the forecast period can be attributed to the increasing global prevalence of cancer, an aging population, a rising incidence of non-small cell lung cancer, a surge in pancreatic and metastatic breast cancer cases, and a growing number of patients eligible for combination chemotherapy. Key trends expected during this period include ongoing clinical trials investigating new drug combinations and indications, expanded use in combination therapies with agents including cisplatin, carboplatin, and paclitaxel, advancements in drug delivery systems, improved formulation technologies aimed at reducing toxicity, and increased automation in pharmaceutical manufacturing processes.

The increasing incidence of breast cancer is expected to drive the growth of the gemcitabine hydrochloride market in the coming years. Breast cancer originates in the cells of the breast, typically within the milk ducts or glands. As life expectancy rises, the risk of breast cancer also increases, primarily due to the greater likelihood of genetic mutations accumulating with age. Gemcitabine hydrochloride plays a vital role in breast cancer treatment by disrupting DNA replication, thereby slowing the rapid proliferation of abnormal cells. For example, in September 2024, the Australian Government reported that an estimated 20,640 individuals in Australia were expected to be diagnosed with breast cancer in 2022, including 212 males and 20,428 females. The overall lifetime risk of being diagnosed with breast cancer by age 85 was projected at 1 in 15 (6.7%) - 1 in 668 (0.15%) for men and 1 in 8 (13%) for women. This rising prevalence underscores the growing demand for effective treatments, including gemcitabine hydrochloride.

Leading companies in the gemcitabine hydrochloride market are advancing cancer treatment by developing innovative approaches such as perioperative immunotherapy to improve therapeutic outcomes. Perioperative immunotherapy involves administering treatment both before (neoadjuvant) and after (adjuvant) surgery to enhance effectiveness and lower the risk of cancer recurrence. For example, in March 2025, AstraZeneca, a UK-based pharmaceutical company, received U.S. Food and Drug Administration (FDA) approval for Imfinzi (durvalumab), marking it as the first and only approved perioperative immunotherapy for muscle-invasive bladder cancer (MIBC). The treatment protocol includes a combination of Imfinzi with chemotherapy agents - gemcitabine and cisplatin - prior to surgery, followed by continued use of Imfinzi post-surgery. Clinical trials demonstrated that this approach significantly improved survival rates and reduced the includinglihood of recurrence, highlighting the transformative potential of such combination therapies in oncology.

In December 2024, Cheplapharm, a pharmaceutical company based in Germany, acquired Gemzar from Eli Lilly for an undisclosed amount. This acquisition enhances Cheplapharm's oncology portfolio by adding Gemzar, a well-established chemotherapy drug used to treat a range of cancers, including non-small cell lung cancer, pancreatic cancer, and breast cancer. Eli Lilly and Company is a US-based manufacturer of gemcitabine hydrochloride, commonly known as Gemzar.

Major players in the gemcitabine hydrochloride market are Fresenius Kabi, Eli Lilly and Company, Teva Pharmaceutical Industries Ltd., Intas Pharmaceuticals Ltd., Mylan NV, Accord Healthcare, Sandoz Group AG, Sun Pharmaceutical Industries Ltd., Apotex Inc., Dr. Reddy’s Laboratories, Cipla Ltd., Amneal Pharmaceuticals, Alkem Laboratories, Gland Pharma Ltd., Strides Pharma Science Ltd., Shilpa Medicare Ltd., ScinoPharm Taiwan Ltd., Orchid Pharma Ltd., Arevipharma GmbH, and Qilu Pharmaceutical Co. Ltd.

North America was the largest region in the gemcitabine hydrochloride market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in gemcitabine hydrochloride report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.

The countries covered in the gemcitabine hydrochloride market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

The gemcitabine hydrochloride market consists of sales of pharmaceutical intermediates, generic injectable drugs, and formulation development kits. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

Gemcitabine hydrochloride is a synthetic nucleoside analog that disrupts DNA synthesis, thereby preventing cell division. Due to its ability to integrate into DNA strands and halt replication, it is widely used in research focused on cellular replication. Once inside the cell, gemcitabine is phosphorylated into its active form, becomes incorporated into DNA, causes chain termination, and ultimately initiates programmed cell death.

The primary product types of gemcitabine hydrochloride include injections, solutions, and other forms. The injection form is delivered directly into the bloodstream using a syringe or intravenous (IV) method and may also be administered subcutaneously or intramuscularly. Distribution channels include hospital pharmacies, retail pharmacies, online pharmacies, and specialty clinics. It is used in the treatment of various cancers, including pancreatic cancer, non-small cell lung cancer, bladder cancer, breast cancer, ovarian cancer, and others.

The gemcitabine hydrochloride market research report is one of a series of new reports that provides gemcitabine hydrochloride market statistics, including gemcitabine hydrochloride industry global market size, regional shares, competitors with a gemcitabine hydrochloride market share, detailed gemcitabine hydrochloride market segments, market trends and opportunities, and any further data you may need to thrive in the gemcitabine hydrochloride industry. This gemcitabine hydrochloride market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

The gemcitabine hydrochloride market size has grown strongly in recent years. It will grow from $0.78 billion in 2024 to $0.84 billion in 2025 at a compound annual growth rate (CAGR) of 7.3%. The growth observed during the historic period can be attributed to several factors, including the expansion of early-stage cancer detection programs, the development of oncology drug distribution networks, increased access to treatment through both public and private healthcare systems, greater inclusion of gemcitabine hydrochloride in hospital oncology formularies, and a general rise in global healthcare expenditures.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 3-5 business days.